Epidemiology, Microbiology, and Risk Factors of Bacterial Bloodstream Infections in Patients After Allogeneic Hematopoietic Stem Cell Transplantation
DOI: https://doi.org/10.2147/idr.s451781
2024-04-21
Infection and Drug Resistance
Abstract:Ruonan Zhang, Yiying Xiong, Linyi Zhang, Lin Liu Department of Hematology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China Correspondence: Lin Liu, Email Purpose: To investigate the clinical characteristics, etiology, and risk factors of bacterial bloodstream infection (BSI) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. This study also aimed to provide a clinical basis for early identification of high-risk patients and optimization of empirical antimicrobial treatment. Patients and Methods: This is a retrospective study of clinical data during agranulocytosis from 331 patients with hematological malignancies who underwent allo-HSCT at our institute between January 2016 and December 2022. The incidence, distribution and drug resistance patterns, and the risk factors of BSI were analyzed. Results: Among the 331 HSCT patients, 250 had febrile neutropenia and 45 cases were found to have BSI. The incidence of BSI in patients with agranulocytosis fever was 18% (45/250). A total of 48 pathogens were isolated during BSI episodes, gram-negative bacteria (GNB) accounted for 70.8% (34/48), gram-positive bacteria (GPB) for 29.2% (14/48). Multivariate analysis revealed that ≥grade 2 acute graft-versus-host disease (aGVHD) and previous BSI within 6 months before HSCT were independently associated with an increased occurrence of BSI. Coagulase-negative staphylococci (CoNS) and Escherichia coli were the most commonly isolated GPB and GNB, respectively. A total of 32 GNB were tested for drug susceptibility, the detection rate of carbapenem-resistant Enterobacteriaceae (CRE) was 12.5% (4/32), and extended-spectrum β-lactamase (ESBL) accounted for 56.3% (18/32). Conclusion: BSIs are still a common and severe complication after allo-HSCT. In our center, BSIs in allo-HSCT patients are dominated by gram-negative bacteria and the resistance rate to carbapenem drugs is high. Risk factors for BSI during agranulocytosis were previous BSI within 6 months before HSCT and ≥grade 2 aGVHD. Keywords: allogeneic hematopoietic stem cell transplantation, bloodstream infection, pathogenic bacteria, antibiotic resistance patterns, risk factors Allogeneic hematopoietic stem cell transplantation (allo-HSCT), as a mature treatment method, has been widely used in the treatment of various hematological malignancies, bone marrow failure syndrome and severe immune deficiency diseases. Nevertheless, the risk of infection is significantly increased due to immunosuppression, neutrophilic deficiency, long-term central venous catheter retention and mucositis caused by high-dose chemoradiotherapy during the process of transplantation. 1 Bacterial bloodstream infection (BSI) refers to systemic inflammatory response syndrome caused by the toxins and metabolites produced by pathogenic microorganisms after they invade the blood circulation system and grow and reproduce, which can lead to sepsis and multiple organ failure in severe cases. 2 Specifically, BSI is a common infectious complication in the early stage of allo-HSCT, with a reported incidence of 13.6% to 38.9%. 3–5 Despite significant advances in the management of transplant-related infections, BSI remains an important cause of non-relapse death in HSCT patients, and the crude mortality rate can reach up to 50%. 6 Additionally, with the widespread utilization of broad-spectrum antibiotics, the emergence and prevalence of multi-drug-resistant bacteria (MDR) has become a major challenge in the field of global public health. Despite numerous published studies on risk factors for BSI, many controversies exist among them, not all studies are in agreement. Moreover, the resistance patterns differ between transplantation centers, which is of particular importance considering the globally increasing rate of gram-negative BSI in allo-HSCT recipients during the last decades. 7 Hence, we conducted a study to evaluate the prevalence, risk factors, distribution and drug resistance of pathogenic bacteria of BSI during neutropenia in allo-HSCT patients. In this retrospective single-center study, we analyzed all BSI episodes occurring in allo-HSCT patients with neutropenia in the Hematology Department of the First Affiliated Hospital of Chongqing Medical University from January 2016 to December 2022. Patients with a fungal infection, contaminant result, or primary graft failure, excluded from this study. This study also did not evaluate BSI episodes occurring after the day of the second HSCT. Transplantations were performed according to institutional protocols, and the choice of conditioning regimen was based on the patient's age, underlying disease and pre-existing comorb -Abstract Truncated-
pharmacology & pharmacy,infectious diseases